BioSpace News Archive

Drug Development

Athira Pharma Extends Study Duration for Alzheimer’s Study

Athira Pharma announced the duration of its open-label study of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s Disease (AD) has been increased from six months to eighteen months.

May 9, 2022
·
2 min read
·
Hayley Shasteen
The Rise and Expansion of Cytokine-based Therapy

Some cytokines can stimulate the immune system, while others slow it down. Here’s a look at the latest news on cytokine data and therapy developments.

May 9, 2022
·
4 min read
·
Mark Terry
Business

Aspen Reels in $147.5M to Advance Personalized Parkinson’s Therapy

Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.

May 9, 2022
·
3 min read
·
Mark Terry
bit.bio Launches Novel Cell Model for Huntington’s Disease

bit.bio announced Monday that it has launched its Huntington’s Disease (HD) cell model to accelerate drug discovery and screening for patients with the disease.

May 9, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective

OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.

May 9, 2022
·
4 min read
·
Gail Dutton
Policy

The Reason Biotech M&As Aren’t Materializing

Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.

May 9, 2022
·
3 min read
·
Alex Keown
Business

Janssen Dissolves HPV, HBV Collaboration with Bavarian Nordic

Janssen discontinued the development partnership due to advancements made by other companies against the human papillomavirus and its own changing strategic priorities.

May 9, 2022
·
2 min read
·
Alex Keown
Business

BioSpace Speaks with R&D Leaders for World Lupus Day

In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.

May 9, 2022
·
8 min read
·
Hayley Shasteen
Drug Development

BioNTech Forges Ahead in Oncology, Infectious Disease

BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.

May 9, 2022
·
3 min read
·
Alex Keown
Drug Development

LogicBio Cleared to Continue Dosing in Pediatric MMA Trial

LogicBio Therapeutics has received the green light to continue dosing participants in its Phase I/II Sunrise trial, following a clinical hold placed by the FDA due to adverse events in pediatric patients.

May 9, 2022
·
2 min read
·
Jazmine Colatriano, M.S.